| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.
According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.
Posted In: MRVI
